A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tablets) in patients with painful knee osteoarthritis, Kellgren-Lawrence grade 3 by X-ray
- Conditions
- Prevention and treatment of disease modifying osteoarthritisMedDRA version: 6.1Level: PTClassification code 10024776
- Registration Number
- EUCTR2004-001754-92-IT
- Lead Sponsor
- OVARTIS FARMA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method